Skip to main content
. 2012 Aug 28;7(8):e44254. doi: 10.1371/journal.pone.0044254

Figure 4. Cotreatment with FANCF shRNA and MX inhibits BCRP expression by activating the p38 MAPK pathway.

Figure 4

(A) Total cellular proteins (50 μg) from exponentially growing cells treated as indicated in the figure were subjected to western blot analysis with antibodies directed against the proteins or their phosphorylated form as indicated. β-actin was applied as control for equal loading. (B) MCF-7 and T-47D cells were pre-treated with the JNK inhibitor SP600125 or p38 inhibitor SB203580 for 2 h, and then whole lysates from cells treated as indicated in figure were subjected to western blot analysis with BCRP antibody. (C) Densitometric analysis was done for BCRP expression. Results were normalized to β-actin values. Graphs show means ± S.D. of three independent experiments. P values, # P<0.05 versus transfected with FANCF shRNA and MX in cells.